China Animal Husbandry Industry Valuation
Is 600195 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 600195 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 600195 (CN¥11.48) wird über unserer Schätzung des Fair Value (CN¥4.68) gehandelt.
Deutlich unter dem Marktwert: 600195 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600195?
Other financial metrics that can be useful for relative valuation.
| What is 600195's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥10.16b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 18.7x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 600195's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16x | ||
600993 Mayinglong Pharmaceutical Group | 20.6x | n/a | CN¥9.9b |
002020 Zhejiang Jingxin Pharmaceutical | 14.9x | 14.9% | CN¥9.2b |
000650 Renhe Pharmacy | 14x | n/a | CN¥9.2b |
002332 Zhejiang Xianju PharmaceuticalLtd | 14.3x | 17.5% | CN¥9.9b |
600195 China Animal Husbandry Industry | 18.6x | 20.9% | CN¥10.2b |
Price-To-Earnings gegen Gleichaltrige: 600195 ist auf der Grundlage des Price-To-Earnings Verhältnisses (17.3x) im Vergleich zum Durchschnitt der Vergleichsgruppe (15.5x) teuer.
Price to Earnings Ratio vs Industry
How does 600195's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 600195 ist aufgrund seines Price-To-Earnings Verhältnisses (21.4x) im Vergleich zum CN Pharmaceuticals Branchendurchschnitt (31.3x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 600195's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.6x |
| Fair PE Ratio | 24.3x |
PM vs. Fair Ratio: 600195 ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (21.4x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (30.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥9.95 | CN¥13.72 +37.9% | 22.6% | CN¥18.90 | CN¥9.60 | n/a | 6 |
| Mar ’25 | CN¥9.54 | CN¥14.20 +48.8% | 17.9% | CN¥18.90 | CN¥11.50 | n/a | 6 |
| Feb ’25 | CN¥9.02 | CN¥14.20 +57.4% | 17.9% | CN¥18.90 | CN¥11.50 | n/a | 6 |
| Jan ’25 | CN¥11.86 | CN¥14.20 +19.7% | 17.9% | CN¥18.90 | CN¥11.50 | n/a | 6 |
| Dec ’24 | CN¥11.47 | CN¥14.20 +23.8% | 17.9% | CN¥18.90 | CN¥11.50 | n/a | 6 |
| Nov ’24 | CN¥11.14 | CN¥14.38 +29.1% | 16.5% | CN¥18.90 | CN¥11.50 | n/a | 6 |
| Oct ’24 | CN¥11.29 | CN¥14.50 +28.4% | 16.2% | CN¥18.90 | CN¥11.50 | n/a | 6 |
| Sep ’24 | CN¥11.64 | CN¥14.38 +23.6% | 17.5% | CN¥18.90 | CN¥10.80 | n/a | 6 |
| Aug ’24 | CN¥12.23 | CN¥15.55 +27.1% | 18.7% | CN¥18.90 | CN¥10.80 | n/a | 6 |
| Jul ’24 | CN¥11.68 | CN¥15.55 +33.1% | 18.7% | CN¥18.90 | CN¥10.80 | n/a | 6 |
| Jun ’24 | CN¥12.37 | CN¥15.82 +27.9% | 17.0% | CN¥18.90 | CN¥10.80 | n/a | 6 |
| May ’24 | CN¥13.00 | CN¥16.93 +30.3% | 8.9% | CN¥18.90 | CN¥14.20 | n/a | 6 |
| Apr ’24 | CN¥14.92 | CN¥17.96 +20.4% | 14.9% | CN¥23.00 | CN¥14.20 | CN¥9.73 | 6 |
| Mar ’24 | CN¥15.76 | CN¥17.62 +11.8% | 16.4% | CN¥23.00 | CN¥14.20 | CN¥9.54 | 6 |
| Feb ’24 | CN¥14.14 | CN¥16.55 +17.0% | 10.7% | CN¥19.14 | CN¥14.20 | CN¥9.02 | 5 |
| Jan ’24 | CN¥11.62 | CN¥16.46 +41.7% | 12.0% | CN¥19.14 | CN¥14.20 | CN¥11.86 | 4 |
| Dec ’23 | CN¥13.49 | CN¥16.46 +22.0% | 12.0% | CN¥19.14 | CN¥14.20 | CN¥11.47 | 4 |
| Nov ’23 | CN¥13.66 | CN¥16.11 +17.9% | 15.0% | CN¥19.14 | CN¥12.80 | CN¥11.14 | 4 |
| Oct ’23 | CN¥13.16 | CN¥15.53 +18.0% | 11.7% | CN¥17.50 | CN¥12.80 | CN¥11.29 | 4 |
| Sep ’23 | CN¥13.40 | CN¥15.53 +15.9% | 11.7% | CN¥17.50 | CN¥12.80 | CN¥11.64 | 4 |
| Aug ’23 | CN¥11.21 | CN¥13.77 +22.8% | 6.7% | CN¥15.00 | CN¥12.80 | CN¥12.23 | 3 |
| Jul ’23 | CN¥12.30 | CN¥13.07 +6.2% | 13.6% | CN¥15.00 | CN¥10.70 | CN¥11.68 | 3 |
| Jun ’23 | CN¥12.34 | CN¥13.07 +5.9% | 13.6% | CN¥15.00 | CN¥10.70 | CN¥12.37 | 3 |
| May ’23 | CN¥11.08 | CN¥15.10 +36.3% | 25.5% | CN¥21.20 | CN¥10.70 | CN¥13.00 | 4 |
| Apr ’23 | CN¥12.73 | CN¥15.84 +24.4% | 25.5% | CN¥21.20 | CN¥10.70 | CN¥14.92 | 4 |
Analysten-Prognose: Das Kursziel liegt um mehr als 20% über dem aktuellen Aktienkurs, aber die Analysten liegen nicht in einem statistisch sicheren Bereich der Übereinstimmung.